Explore the words cloud of the ChemoBOOM project. It provides you a very rough idea of what is the project "ChemoBOOM" about.
The following table provides information about the project.
THE UNIVERSITY OF EDINBURGH
|Coordinator Country||United Kingdom [UK]|
|Total cost||183˙454 €|
|EC max contribution||183˙454 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2016-02-01 to 2018-01-31|
Take a look of project's partnership.
|1||THE UNIVERSITY OF EDINBURGH||UK (EDINBURGH)||coordinator||183˙454.00|
The heterogeneity and capacity to evolve in response to treatment of the most aggressive forms of cancer make the selective inhibition of molecular targets an insufficient strategy to reach complete neoplastic remission. In this context, the unspecificity of classic chemotherapeutic agents becomes an advantage for treatment. Nonetheless, due to dose-limiting adverse effects, chemotherapeutic drugs become ineffective against some late-stage primary tumours, which are typically responsible for the death of the patient. To tackle those difficult to treat cancers, improved chemotherapeutic strategies far beyond the one-pill paradigm are mandatory. To reduce systemic side effects while increasing the levels of drug in the disease area, a number of novel methods originated from the Chemical Biology field (rather than from conventional Medicinal Chemistry approaches) have emerged during the last year to explore the site-specific activation of cytotoxic drugs. One of those novel concepts, pioneered by the Unciti-Broceta’s group in Edinburgh, is based on the use of palladium to activate drug precursors by heterogeneous bioorthogonal organometallic (BOOM) catalysis. Using an O-propargylation strategy to mask functional groups essential for the cytotoxic mode of action of clinically-used drugs, I will investigate the development of novel bioorthogonal palladium-labile prodrugs and their reactivation in cancer cell culture by heterogeneous palladium catalysis. With the support of a MSCA-IF, I intent to explore the full scope of this exciting experimental strategy, including the first ever approach designed to release two cytotoxic drugs with synergistic pharmacological activity from a single prodrug molecule.
|year||authors and title||journal||last update|
Ana M. PÃ©rez-LÃ³pez, BelÃ©n Rubio-Ruiz, VÃctor SebastiÃ¡n, Lloyd Hamilton, Catherine Adam, Thomas L. Bray, Silvia Irusta, Paul M. Brennan, Guy C. Lloyd-Jones, Dirk Sieger, JesÃºs SantamarÃa, Asier Unciti-Broceta
Gold-Triggered Uncaging Chemistry in Living Systems
published pages: 12548-12552, ISSN: 1433-7851, DOI: 10.1002/anie.201705609
|Angewandte Chemie International Edition 56/41||2019-06-14|
BelÃ©n Rubio-Ruiz, Jason T. Weiss, Asier Unciti-Broceta
Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor
published pages: 9974-9980, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b01426
|Journal of Medicinal Chemistry 59/21||2019-06-14|
BelÃ©n Rubio-Ruiz, Ana M. PÃ©rez-LÃ³pez, Thomas L. Bray, Martin Lee, Alan Serrels, MartÃn Prieto, Manuel Arruebo, Neil O. Carragher, VÃctor SebastiÃ¡n, Asier Unciti-Broceta
High-Precision Photothermal Ablation Using Biocompatible Palladium Nanoparticles and Laser Scanning Microscopy
published pages: 3341-3348, ISSN: 1944-8244, DOI: 10.1021/acsami.7b17282
|ACS Applied Materials & Interfaces 10/4||2019-06-14|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHEMOBOOM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CHEMOBOOM" are provided by the European Opendata Portal: CORDIS opendata.